China's emergence as a second hub of pharmaceutical innovation could trigger massive changes to the global drug market, including how treatments are regulated and priced in the U.S.
Why it matters: More cutting-edge therapies are generally a good thing for patients, regardless of where they come from. But the new world order could spark questions over who'll access those therapies and where money flows.
As the Company Formerly Known as Twitter prepares to go public, its former CEO is raising money for a very different venture.
Driving the news: eMed, an employee telehealth company led by Linda Yaccarino, this morning announced $200 million in new funding at a post-money valuation north of $2 billion.
Trump administration health officials are giving serious consideration to a plan that would make injuries from COVID-19 vaccines a formal diagnosis that can be coded in medical records.
Why it matters: Increasing documentation of what's still a loosely defined condition could help lay the groundwork for future lawsuits against vaccine manufacturers.
